A Phase 2, Randomized, Dose-Ranging Study to Assess the Safety and Anti-Cytomegalovirus Activity of Maribavir versus Valganciclovir for the Treatment of CMV Infections in Transplant Recipients Who Do Not Have CMV Organ Disease
Latest Information Update: 21 Dec 2021
At a glance
- Drugs Maribavir (Primary) ; Valganciclovir
- Indications Cytomegalovirus infections
- Focus Adverse reactions
- Sponsors Shire ViroPharma; ViroPharma Incorporated
- 29 Jul 2020 Results assessing the viral mutations and associated drug resistance phenotypes detected at baseline and after maribavir therapy in patients enrolled in trials 202 and 203 published in the Journal of Infectious Diseases
- 24 Sep 2019 According to a Takeda Pharma media release, Johan Maertens (M.D., Ph.D. of Universitaire Ziekenhuizen Leuven in Leuven, Belgium) is the trials principal investigator and lead author.
- 24 Sep 2019 Results presented in a Takeda Pharma media release.